infliximab oral (TH023) - Celltrion, Tharimmune, Intract Pharma
nalmefene (TH-104) - Tharimmune
https://www.accessnewswire.com/newsroom/en/biotechnology/tharimmune-issues-comprehensive-corporate-update-including-lead-th104-as-critical-nat-1055981
 
Aug 4, 2025
 
Next